Phebra is one of Australia’s largest privately-owned pharmaceutical groups, with a manufacturing facility in Sydney which develops, produces and markets critical medicines in Australia and across the world. Since 1993, Phebra has built a reputation for innovation, product development and manufacture of over 65 medicines in critical therapeutic disease areas such as cystic fibrosis, antidotes, diagnostics, oncology and pain. Being dynamic and innovative, Phebra collaborates with healthcare providers to research, develop and produce critical medicines to meet unmet needs.